Newron updated valuation report "Back to pivotal"

Wednesday, January 4, 2023 @ 12:00 am

Despite exciting interim results of “Studies 014/015” of evenamide in TRS, Newron trades just above its cash value. Xadago and evenamide are virtually free. Clinical progress of evenamide in schizophrenia and Xadago in PD-LID should add to the value while reducing the clinical development risk. Key catalysts include:

1. Full results “Study 014” of evenamide in TRS (March 2023)
2. Start new label trial Xadago in PD-LID (H1 2023)
3. Results pivotal “Study 008A” of evenamide in non-TRS (H2 2023)

Read full Newron valuation report

You may also be interested in

Beware of fraudulent emails impersonating the Swiss Biotech Association

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We recently noticed fraudulent emails to steal your passwords of your Microsoft, Outlook or similar accounts via phishing emails. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals will ask y
October 8, 2024

Vandria becoming clinical stage company: First clinical trial for neurodegenerative disorders

Vandria SA, a company at the vanguard of mitochondrial therapeutics developing first-in-class small molecule mitophagy inducers, today announces that the first subjects have been dosed in its first-in-human clinical trial of its lead Central Nervous System (CNS) compound VNA-318. Readout of this combined single and multiple ascending dose trial is expected in the summer of 2025.
December 18, 2024

BioCopy's CEO Matthias Wiedenfels among Germany's biotech pioneers of the coming decade

BioCopy CEO Matthias Wiedenfels honored as winner of "Germany's 30 by 2030" award.
December 17, 2024

The co-founders of AlphaMol are ranked as the "top 2% scientists" in the world

December 16, 2024

Porton Pharma Solutions: Collaboration with Aojin Life Sciences in China and USA

December 13, 2024

MedScienceSwiss: Combatting antibiotic-resistant bacteria with “Plan B”

MedScienceSwiss is developing a non-pharmaceutical therapy for the treatment of antibiotic-resistant bacteria. The goal: to significantly reduce the number of deaths in hospitals due to nosocomial (difficult-to-treat) infections. The technology is not only intended to serve as an alternative to the current plan A (antibiotics), but also to function as a general approach to the treatment of resista
December 3, 2024